• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

WHO - Identification and management of Guillain-Barr? syndrome in the context of Zika virus Interim guidance - February 25, 2016

sharon sanders

Editor-in-Chief & President
[h=1]Identification and management of Guillain-Barr? syndrome in the context of Zika virus[/h] [h=2]Interim guidance[/h]
Print

Authors:
World Health Organization


gbs.jpg

[h=3]Publication details[/h] Number of pages: 3
Publication date: 25 February 2016
Languages: English
WHO reference number:WHO/ZIKV/MOC/16.4

[h=3]Downloads[/h]




[h=3]Overview[/h] Guillain-Barr? syndrome (GBS) is a disorder in which the body?s immune system attacks part of the peripheral nervous system. GBS can be triggered by a variety of infections, including dengue and chikungunya viruses. The syndrome can affect the peripheral nerves that control muscle strength as well as those that transmit feelings of pain, temperature and touch. This can result in muscle weakness and loss of sensation in the legs and/or arms. Approximately 25% of GBS patients require intensive care and 3-5% die even with appropriate supportive care, due to complications related to: paralysis of the muscles that control breathing; cardiac arrest; or blood clots.
This document aims to provide interim guidance on the case definition of GBS and strategies to manage the syndrome, in the context of Zika virus and its potential association with GBS. This document is intended to inform the development of local clinical protocols and health policies related to the care of patients with GBS. An expert meeting will be organized in March 2016 to develop additional guidance to identify and manage GBS and other possible neurological disorders in the context of Zika virus transmission.
[h=4]Related links[/h]

http://www.who.int/csr/resources/publications/zika/guillain-barre-syndrome/en/

 
Back
Top